A Phase 1/1b Open-Label Dose Escalation And Expansion Study Of Bcl-2 Inhibitor BGB-11417 In Patients With Mature B-Cell Malignancies Read more
A Phase 1a/1b Dose Escalation And Expansion Trial Of TTI-621, A Novel Biologic Targeting CD47, In Subjects With Relapsed Or Refractory Hematologic Malignancies And Selected Solid Tumors Read more
A Phase 2, Multicenter, Single-Arm Study Of Zanubrutinib (BGB-3111) In Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant Of Prior Treatment With Ibrutinib Read more
A Phase 1b/2 Open-Label, Dose Escalation And Expansion Study Of Orally Administered Vrx-3996 And Valganciclovir In Subjects With Epstein-Barr Virus-Associated Lymphoid Malignancies Read more
A Phase 3, Randomized, Double Blind, Placebo Controlled, Multicenter Study Of Bendamustine And Rituximab (BR) Alone Versus In Combination With Acalabrutinib (ACP 196) In Subjects With Previously Untreated Mantle Cell Lymphoma Read more
A Phase I Trial Assessing The Feasibility Of Romidepsin Combined With Brentuximab Vedotin For Patients With Requiring Systemic Therapy For Cutaneous T-Cell Lymphoma Read more
A Phase 1/2, Open-Label, Dose-Escalation Trial Of GEN3013 In Patients With Relapsed, Progressive Or Refractory B-Cell Lymphoma Read more
Outcomes Of Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Patients: Real World Experience In Lymphoma Patients Read more
